Cancer chemotherapy can reach a new level

Cancer chemotherapy can reach a new level

Delivery of the active compounds of chemotherapy in cancer cells is one of the major challenges of today's medicine. But even more the main difficulty is to make cancer cells "swallow" chemicals that will kill them. It seems that this important task was to decide scientists of America.

 In the latest issue of the American Cancer Community «Nano» it was reported that the joint team of researchers from nanotechnology Central Hospital in Massachusetts, the Women's Hospital and the Brigheym hospital together with scientists at MIT has developed a system that can effectively deliver an incredible amount of chemotherapeutic drugs in prostate cancer cells. The research was led by Dr. Omid Farokzad (Omid Farokhzad) from the Department of Perioperative anesthesiologists.

Scientists have, figuratively speaking, created a self-propelled and equipped with self-discharging car, which placed medication and sent straight into a cancer cell!

To develop a "car" experimenters have used a team developed Farokzad breeding strategy. Thanks to this innovative method, they were able to create specific ligands, which can be attached to the nanoparticles containing chemotherapeutic agents. In a study of this drug was of vegetable origin taxane docetaxel.

Assembled by a team of Farokzad ligands differs in two important characteristics. First, they have the ability to distinguish between cancerous and healthy cells, which is very important for an effective oncotherapy. And, secondly, to make sure that the cancer cells are "willingly swallow." "Most of the ligands are absorbed by cells, but very slowly and inefficiently. – We have developed a ligand specifically designed for easy absorption, "- says Farokzad.

An additional advantage offered by American scientists therapeutic approach is the ability of new ligands – plural carriers of nanoparticles interact with different antigens (tumor marker) on the cell surface. Other known methods now using nanoparticles involve the use of ligands that are able to identify specific, well-known markers.

"The research we have developed is a unique strategy to detect cancer cells and efficiently deliver drugs to them, even if the markers are not known to us, – said study lead author, researcher at the Laboratory of Nanomedicine and Biomaterials Women's Hospital and the hospital doctor Brigheym Zeya Xiao. – Our method simplifies the process of developing targeted nanoparticles and extends the range of their application in oncotherapy. "

Leave a Reply